Virginie Hivert, Director of Therapeutic Development at Eurordis, was recently interviewed by Phamaceutiques – the reputable French magazine that focuses on politics, economics, and innovation in the life sciences space. During the interview, Hivert introduced the objectives of REMEDi4ALL as well as some of the barriers to implementing drug repositioning.
“We often tend to oppose innovation to repositioning, but the latter approach can bring innovation”.
Hivert also shared REMEDi4ALL’s patient-centric philosophy, especially highlighting their involvement in the selection and implementation of the projects under the REMEDi4ALL, where patients will be included in a more co-creative role.
“For each project we want to form a real team associating scientists and patients“
Read the article (in French) here.
